Why giant moa — a bird that once towered over humans — are even harder to de-extinct than dire wolves
A biotech company that claims to have brought dire wolves back from extinction has announced plans to resurrect giant extinct birds called moa. However, experts say that dire wolves were never truly resurrected, and that moa will be even harder to de-extinct.
Earlier this month, Texas-based Colossal Biosciences said it had teamed up with filmmaker Sir Peter Jackson and Indigenous partners to bring back the 12-foot-tall (3.6 meter) South Island giant moa (Dinornis robustus) and other moa species. These flightless birds roamed New Zealand until they were hunted to extinction by early Māori settlers around 600 years ago.
The new project will be coordinated by the Ngāi Tahu Research Centre, a joint venture between the main Māori tribe (iwi) on the South Island of New Zealand and the University of Canterbury in Christchurch. It's a multifaceted project that aims to combine traditional Māori knowledge, wildlife conservation and genetic engineering-driven de-extinction.
However, the project has already come under fire. Critics have highlighted that some Māori iwi oppose de-extinction, while several scientists have argued that genetically modifying living animals can't bring back lost species. The scientific criticism is similar to the commentary after Colossal unveiled its "dire wolves" — a species that went extinct more than 10,000 years ago.
Colossal's "dire wolves" are genetically modified gray wolves (Canis lupus) with 20 gene edits. The company claims they are dire wolves (Aenocyon dirus) because they have some observable traits identified in the dire wolf genome, such as increased size and a white coat. However, genetically, they're still mostly gray wolves. The same will be true for the living animal Colossal modifies for the moa project — but for moa, it's even more complicated.
Related: T. rex researchers eviscerate 'misleading' dinosaur leather announcement
Moa's closest living relatives are a group of South American birds called tinamous. The largest tinamou species is smaller than most domestic chickens, so is minuscule compared to South Island giant moa. Australia's emus (Dromaius novaehollandiae) are the next closest relative, but while these large flightless birds are physically more similar to giant moa, they're still not as big, growing to an average of 5.7 feet (1.75 m) tall. Both of these living relatives also separated from moa a long time ago.
"The common ancestor of the moa and tinamou lived 58 million years ago, while the common ancestor of moa and emu lived 65 million years ago," Nic Rawlence, director of the Otago Palaeogenetics Lab at the University of Otago in New Zealand and a critic of the moa plan, told Live Science in an email. "That's a lot of evolutionary time."
To put that in context, dire wolves only split from modern wolf-like canids — the group that includes gray wolves — around 5.7 million years ago (or even more recently at 4.5 million years ago, according to a recent preprint involving some of Colossal's scientists). That means moa had a lot more time to evolve unique traits.
Image 1 of 3
Image 2 of 3
Image 3 of 3
Rawlence explained that moa and their closest living relatives descended from a group of small flying birds called lithornids. These animals lived around the world and gave rise to different groups that independently lost the ability to fly. As Rawlence puts it, these flightless birds were "filling the job vacancies in the ecosystem left by the extinction of the dinosaurs."
Moa and emu lost flight through a process called convergent evolution, whereby different organisms evolve similar traits. That means, according to Rawlence, that the physiological and developmental mechanisms behind their body plans evolved independently, potentially via different genetic routes, which poses a challenge when it comes to bringing moa back.
"Genetically engineering specific genes in an emu to match a moa could have dire developmental consequences given this independent and convergent evolutionary history," Rawlence said.
Live Science asked Colossal whether there were any health risks associated with genetically engineering living animals to be more like extinct animals. Colossal's chief science officer, Beth Shapiro, told Live Science that the company was certified by the American Humane Society and that animal welfare was a priority in their work.
"We thoroughly evaluate health risks of any proposed edit before selecting them for our final list of edits," Shapiro said in an email.
Colossal's moa de-extinction plan
Before Colossal begins creating its modern-day moa, the company aims to sequence and rebuild the genomes of all nine extinct moa species, while also sequencing high-quality genomes of their closest living relatives. This will allow Colossal to identify the changes that led to the moa's unique traits, including their large body size and lack of wings, according to Colossal's website.
The researchers will then use primordial germ cells, the precursors of sperm or egg cells, from living species to "build a surrogate bird" and make genetic changes to create birds with moa traits. The company needs both male and female surrogates to carry the sperm and egg of their "moa," to then produce the genetically modified offspring.
Colossal's website states that emus' larger size makes them a more suitable surrogate than tinamous. However, details on this part of the process are limited. Shapiro told Live Science that they were "still in the process of selecting the surrogate species for moa de-extinction."
Emus lay large green eggs, around 5 inches (12 cm) long and 3.5 inches (9 cm) wide. Still, that's nothing compared to a South Island giant moa egg, which were 9.5 inches (24 cm) by 7 inches (17.8 cm).
RELATED STORIES
—'We didn't know they were going to be this cute': Scientists unveil genetically engineered 'woolly mice'
—Colossal's de-extinction campaign is built on a semantic house of cards with shoddy foundations — and the consequences are dire
—Dodos were fast and powerful, not slow and inept, definitive preserved specimen suggests
"A South Island giant moa egg will not fit inside an emu surrogate, so Colossal will have to develop artificial surrogate egg technology," Rawlence said.
Colossal briefly mentioned artificial eggs during its moa announcement, but didn't provide details on this part of the process. Live Science asked Colossal whether they could explain how Colossal will hatch a South Island giant moa.
"Our exogenous development team is exploring different strategies for artificial egg incubation, which will have application both for moa de-extinction and bird conservation work," Shapiro said in an email.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies
(Reuters) -Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases. Matchpoint said on Thursday it will use its technology to develop drugs that block the activity of a specific protein, helping to lower the production of inflammation-causing signals. The company will lead the research and drug development process, using the funding from Novartis. If Novartis exercises its option to exclusively license the program, the drugmaker will have global rights to develop and commercialize all products resulting from the collaboration. Matchpoint said it will receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, and development and commercial milestones. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Bloomberg
6 hours ago
- Bloomberg
AstraZeneca Says Its Automimmune Drug Reduced Disease Severity
AstraZeneca Plc 's experimental drug for a rare autoimmune disorder helped patients control their disease, the company said, boosting prospects for the potential blockbuster medicine. The injectable drug gefurulimab for generalized myasthenia gravis showed a statistically significant and clinically meaningful reduction in disease severity while helping patients improve their ability to carry out daily tasks, AstraZeneca said in a statement.
Yahoo
7 hours ago
- Yahoo
Citryll Announces Formation of Scientific Advisory Board
CITRYLL ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD Oss, Netherlands – 24 July 2025 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), today announces the formation of its Scientific Advisory Board (SAB). The Board will provide strategic guidance and scientific insight as Citryll advances the development of CIT-013, its first-in-class monoclonal antibody, through the clinic. The SAB brings together internationally recognised experts in NET biology, pre-clinical development, and immunology. The founding members include Dr. Tim Hammond, Professor John Hamilton, Dr. Christian Lood and Professor Paul Kubes. 'We are honoured to welcome this distinguished group of experts to Citryll's Scientific Advisory Board,' said Eric Meldrum, Chief Scientific Officer of Citryll. 'Their combined expertise will be invaluable as we advance CIT-013 in ongoing trials in rheumatoid arthritis and hidradenitis suppurativa. With their guidance, we aim to unlock the full therapeutic potential of targeting extracellular traps in a range of inflammatory diseases. This is an important step in strengthening our broader advisory network, as we also work to build a Clinical Advisory Board to support our next stage of clinical development.' Members of Citryll's Scientific Advisory Board include: Dr. Tim Hammond, PhD Tim brings over 35 years of experience in pharmaceutical drug discovery and development. He is currently Head of Safety at various companies and was formerly Vice President of Safety Assessment in the UK for AstraZeneca. He has been an independent consultant since 2012. Tim is a past President of the British Toxicology Society, is a Fellow of the Royal College of Pathologists, is a member of the American Society of Toxicology and was a founding member of the International Safety Pharmacology Society, which awarded him the Distinguished Scientist Award in 2007. He holds a PhD in Pharmacology and Toxicology from the University of Birmingham and an Honorary Professorship from the University of Liverpool. Professor John Hamilton, PhD John is internationally recognised for his expertise in macrophage biology and inflammation, with his research significantly contributing to the understanding of inflammatory mechanisms in diseases such as rheumatoid arthritis. He has received numerous honours, including the Australian Rheumatology Association Distinguished Service Medal, the American College of Rheumatology Distinguished Basic Investigator Award, and the International Association of Inflammation Societies Lifetime Achievement Award. He is a Professor in the Department of Medicine at the University of Melbourne and a Fellow of the Australian Academy of Science. He holds a PhD in Chemistry from the University of Melbourne. Dr. Christian Lood, PhD Christian is a leading researcher in neutrophil function, NET formation, and the role of innate immunity in autoimmune diseases such as systemic lupus erythematosus. His work has provided critical insights into how NETs contribute to autoimmune pathology and therapeutic intervention opportunities. He is currently an Associate Professor, Division of Rheumatology at the University of Washington with a focus in neutrophil biology in inflammatory and autoimmune conditions. He holds a PhD in Biomedicine from Lund University. Professor Paul Kubes, PhD Professor Paul Kubes is known internationally for his expertise in leukocyte recruitment and inflammation, with significant contributions to understanding immune cell function in inflammatory disease and tissue repair. He is a professor at Queen's University, where he recently accepted a Canada Excellence Research Chair. Prior to this, he was a Professor at the University of Calgary Cumming School of Medicine and the Founding Director of the Snyder Institute for Chronic Disease for 15 years. He also holds a Canada Research Chair in Leukocyte Recruitment in Inflammatory Disease. Professor Paul Kubes has received numerous awards, including the CIHR Investigator of the Year and the Henry Friesen Award, and has published in leading journals such as Cell, Science, and Nature. He holds a (Honours) in Biological Sciences, an M.S. in Physiology, and a Ph.D. in Physiology from Queen's University. -ENDS- About Citryll Citryll is pioneering a transformative approach to treating inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), a fundamental component of the inflammatory process that has yet to be addressed therapeutically. Citryll is developing the first NET-targeting therapy and potentially creating a new class of therapeutics with broad applications across immune-mediated inflammatory diseases. Our lead asset, CIT-013, is a first-in-class monoclonal antibody with a unique dual mechanism of action: it enhances the clearance of existing NETs and inhibits the formation of new NETs. By addressing this key driver of inflammation, CIT-013 has the potential to offer a differentiated and comprehensive treatment option for conditions such as rheumatoid arthritis and hidradenitis suppurativa, where current therapies often fall short of providing adequate disease control. Contacts CitryllSjoerd van Gorp, COOEmail: info@ Citryll Media ContactsICR HealthcareAmber Fennell, Stephanie Cuthbert, Lucy FeatherstoneEmail: citryll@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data